E.e.s. side effects by duration, gender and age - a phase IV clinical study of FDA data

< 1 month:

1. Pyloric stenosis (narrowing of the passage between the stomach and the small intestine)

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Drug hypersensitivity
2. Blood pressure increased
3. Death
4. Drug administration error
5. Dry skin
6. Dyskinesia (abnormality or impairment of voluntary movement)
7. Eye disorder
8. Foot fracture
9. Hereditary angioedema (recurrent episodes of severe swelling)
10. Hospitalisation

female:

1. Abdominal discomfort
2. Alanine aminotransferase increased
3. Blood creatinine increased
4. Blood pressure increased
5. Dry skin
6. Eye disorder
7. Hereditary angioedema (recurrent episodes of severe swelling)
8. Malaise (a feeling of general discomfort or uneasiness)
9. Respiratory disorder (respiratory disease)
10. Drug hypersensitivity

male:

1. Angioedema (rapid swelling of the dermis)
2. Blast cell count increased
3. Drug administration error
4. Drug hypersensitivity
5. Pyloric stenosis (narrowing of the passage between the stomach and the small intestine)
6. Rash
7. Therapeutic response unexpected

0-1:

1. Alanine aminotransferase increased
2. Blood pressure increased
3. Pyloric stenosis (narrowing of the passage between the stomach and the small intestine)

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

1. Drug hypersensitivity

50-59:

1. Drug hypersensitivity
2. Angioedema (rapid swelling of the dermis)
3. Dyskinesia (abnormality or impairment of voluntary movement)
4. Hereditary angioedema (recurrent episodes of severe swelling)
5. Therapeutic response unexpected

60+:

1. Drug hypersensitivity
2. Anxiety
3. Blast cell count increased
4. Blood creatinine increased
5. Eye disorder
6. Hypertension (high blood pressure)